Year-end earn­ings show tur­bu­lent times for Hal Bar­ron's Glax­o­SmithK­line turn­around

Hal Bar­ron and Em­ma Walm­s­ley’s big Glax­o­SmithK­line piv­ot may ul­ti­mate­ly prove suc­cess­ful, de­liv­er­ing block­busters in can­cer, au­to-im­mune con­di­tions and in­fec­tious dis­ease. But the path to get there is al­ready look­ing rocky.

GSK an­nounced their year-end earn­ings Wednes­day morn­ing, re­veal­ing that they had cut two more pipeline can­di­dates af­ter they failed in ear­ly stage tri­als and dis­ap­point­ing in­vestors with news that prof­its had fall­en and earn­ings per share would de­cline by mid to high sin­gle dig­its.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER